All financings
COMPANY TRANSACTIONS

Lantern Pharma Inc.

LTRNNasdaqBiotechnology

Deal details

1 transaction in the database

TRANSACTION REPORT · SEC DISCLOSURES
Gross proceeds$4.0M
Offering price$1.09
Discount to prior close0%
Warrant coverage100%
Placement agent / underwriterRodman & Renshaw LLC

Transaction overview

01

Lantern Pharma Inc. completed a $4.0M registered direct at $1.09 per share. Rodman & Renshaw LLC acted as exclusive placement agent for the financing.

Financing type
Registered Direct
Announcement date
Sep 29, 2026
Pricing date
Sep 29, 2026
Closing date
Sep 30, 2026
Filing date
Sep 30, 2026
Status
Closed
Market cap before announcement
$13.5M
Prior closing price
$1.09
Raise as % of market cap
29.5%

Market data · FMP

Historical market cap
$13,541,259
Market date
Sep 28, 2026
Closing price
$1.09
Latest reported shares outstanding
12,759,146
Latest reported float shares
9,594,424
Share-data date
Oct 1, 2026

Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 2, 2026.

Financial Modeling Prep ↗

Financing terms

02

Equity

Common shares issued
1,469,725
Price per share
$1.09
Pre-funded warrants
2,200,000
Pre-financing shares disclosed in filing
—
Shares outstanding after financing
—

Investor warrants

Warrant shares
3,669,725
Cash exercise price
$1.09
Term
Five years after the stockholder-approval initial exercise date; not five years from closing.
Initial exercisability
—
Beneficial ownership limits
—

Fees & transaction economics

03
Placement agent / underwriting fee
7%
Agent fee amount
$280,000
Management fee
—
Other offering expenses (estimated)
—
Net proceeds (estimated)
—
Net proceeds as % of gross
—

Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.

7% cash placement fee; agent warrants equal to 5% of securities sold, with the exact whole-share allocation undisclosed; expense reimbursement amount undisclosed. A separate 3% fee applies to future cash exercises of investor warrants.

Transaction participants

04
Investor names: —

Source documents

05

SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.

424B5 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-10.1 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-4.1 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-4.2 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-4.3 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-5.1 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-99.1 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
EX-99.2 · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
8-K · Lantern Pharma Inc.SEC filing · Sep 30, 2026
Open source ↗
FMP historical market data · LTRNMarket data · Sep 28, 2026
Open source ↗
SEC deal terms · FMP market data where available · Initial research sample, not complete market coverage. AI-assisted source review; original evidence is available in each report. Names and tickers reflect the transaction date. A dash (—) means the value is unavailable.